| 产品描述: | Mitiperstat是一种强效的骨髓过氧化物酶(MPO)抑制剂。Mitiperstat对预防如心力衰竭和冠状动脉疾病类的心血管疾病有很好的效果。 |
| 靶点: |
GlutathionePeroxidase |
| 体内研究: |
AZD4831 (5 mg) inhibits extracellular myeloperoxidase, decreases inflammation, and improves microvascular function in preclinical disease models. |
| 参考文献: |
1. Joanna Parkinson, et al. The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses. Pharmacol Res Perspect. 2024 Apr;12(2):e1184. 2. Lars H Lund, et al. Rationale and design of ENDEAVOR: A sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction. Eur J Heart Fail. 2023 Sep;25(9):1696-1707. 3. Carolyn S P Lam, et al. Myeloperoxidase Inhibition in Heart Failure With Preserved or Mildly Reduced Ejection Fraction: SATELLITE Trial Results. J Card Fail. 2024 Jan;30(1):104-110. 4. Inghardt T, et al., Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction. J Med Chem. 2022 Sep 8;65(17):11485-11496. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.987 ml |
14.933 ml |
29.867 ml |
| 5 mM |
0.597 ml |
2.987 ml |
5.973 ml |
| 10 mM |
0.299 ml |
1.493 ml |
2.987 ml |
| 50 mM |
0.06 ml |
0.299 ml |
0.597 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |